Effect of valsartan on the incidence of diabetes and cardiovascular events

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Sandström E) > (2010-2014) > Effect of valsartan...

Details
MARC

McMurray, John J (author)

Effect of valsartan on the incidence of diabetes and cardiovascular events

Article/chapterEnglish2010

Publisher, publication year, extent ...

2010
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:umu-50382
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-50382URI
https://doi.org/10.1056/NEJMoa1001121DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. RESULTS: The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). CONCLUSIONS: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

Holman, Rury R (author)
Haffner, Steven M (author)
Bethel, M Angelyn (author)
Holzhauer, Björn (author)
Hua, Tsushung A (author)
Belenkov, Yuri (author)
Boolell, Mitradev (author)
Buse, John B (author)
Buckley, Brendan M (author)
Chacra, Antonio R (author)
Chiang, Fu-Tien (author)
Charbonnel, Bernard (author)
Chow, Chun-Chung (author)
Davies, Melanie J (author)
Deedwania, Prakash (author)
Diem, Peter (author)
Einhorn, Daniel (author)
Fonseca, Vivian (author)
Fulcher, Gregory R (author)
Gaciong, Zbigniew (author)
Gaztambide, Sonia (author)
Giles, Thomas (author)
Horton, Edward (author)
Ilkova, Hasan (author)
Jenssen, Trond (author)
Kahn, Steven E (author)
Krum, Henry (author)
Laakso, Markku (author)
Leiter, Lawrence A (author)
Levitt, Naomi S (author)
Mareev, Viacheslav (author)
Martinez, Felipe (author)
Masson, Chantal (author)
Mazzone, Theodore (author)
Meaney, Eduardo (author)
Nesto, Richard (author)
Pan, Changyu (author)
Prager, Rudolf (author)
Raptis, Sotirios A (author)
Rutten, Guy E H M (author)
Sandström, HerbertUmeå universitet,Allmänmedicin(Swepub:umu)hesa0015 (author)
Schaper, Frank (author)
Scheen, Andre (author)
Schmitz, Ole (author)
Sinay, Isaac (author)
Soska, Vladimir (author)
Stender, Steen (author)
Tamás, Gyula (author)
Tognoni, Gianni (author)
Tuomilehto, Jaako (author)
Villamil, Alberto S (author)
Vozár, Juraj (author)
Califf, Robert M (author)
Umeå universitetAllmänmedicin (creator_code:org_t)

Related titles

In:New England Journal of Medicine362:16, s. 1477-14900028-47931533-4406

Internet link

Find in a library

New England Journal of Medicine (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: McMurray, John J; Holman, Rury R; Haffner, Steven ...; Bethel, M Angely ...; Holzhauer, Björn; Hua, Tsushung A; show more...; Belenkov, Yuri; Boolell, Mitrade ...; Buse, John B; Buckley, Brendan ...; Chacra, Antonio ...; Chiang, Fu-Tien; Charbonnel, Bern ...; Chow, Chun-Chung; Davies, Melanie ...; Deedwania, Praka ...; Diem, Peter; Einhorn, Daniel; Fonseca, Vivian; Fulcher, Gregory ...; Gaciong, Zbignie ...; Gaztambide, Soni ...; Giles, Thomas; Horton, Edward; Ilkova, Hasan; Jenssen, Trond; Kahn, Steven E; Krum, Henry; Laakso, Markku; Leiter, Lawrence ...; Levitt, Naomi S; Mareev, Viachesl ...; Martinez, Felipe; Masson, Chantal; Mazzone, Theodor ...; Meaney, Eduardo; Nesto, Richard; Pan, Changyu; Prager, Rudolf; Raptis, Sotirios ...; Rutten, Guy E H ...; Sandström, Herbe ...; Schaper, Frank; Scheen, Andre; Schmitz, Ole; Sinay, Isaac; Soska, Vladimir; Stender, Steen; Tamás, Gyula; Tognoni, Gianni; Tuomilehto, Jaak ...; Villamil, Albert ...; Vozár, Juraj; Califf, Robert M; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cardiac and Card ...

Articles in the publication: New England Jour ...

By the university: Umeå University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se